# Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

> **NCT00095381** · PHASE2 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 20 (—)

## Conditions studied

- Leukemia, T-Cell

## Interventions

- **DRUG:** forodesine hydrochloride (BCX-1777)

## Key facts

- **NCT ID:** NCT00095381
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2007-03
- **Final completion:** 2007-12
- **Target enrollment:** 20 (—)
- **Last updated:** 2012-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095381, "Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00095381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*